These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29031650)

  • 41. A practice-based observational study identifying factors associated with the use of high-dose tigecycline in the treatment of secondary peritonitis in severely ill patients.
    Maseda E; Suárez-de-la-Rica A; Anillo V; Salgado P; Tamayo E; García-Bernedo CA; Ramasco F; Villagrán MJ; López-Tofiño A; Giménez MJ; Granizo JJ; Hernández-Gancedo C; Aguilar L; Gilsanz F
    Rev Esp Quimioter; 2015 Feb; 28(1):47-53. PubMed ID: 25690145
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgery.
    Song Y; Hu L; Shu Q; Ye J; Liang J; Chen X; Tan L
    Int J Infect Dis; 2018 Oct; 75():82-88. PubMed ID: 30125690
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis.
    Lauf L; Ozsvár Z; Mitha I; Regöly-Mérei J; Embil JM; Cooper A; Sabol MB; Castaing N; Dartois N; Yan J; Dukart G; Maroko R
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):469-80. PubMed ID: 24439136
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
    Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
    Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting.
    Montravers P; Dupont H; Bedos JP; Bret P;
    Intensive Care Med; 2014 Jul; 40(7):988-97. PubMed ID: 24871500
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.
    Poulakou G; Kontopidou FV; Paramythiotou E; Kompoti M; Katsiari M; Mainas E; Nicolaou C; Yphantis D; Antoniadou A; Trikka-Graphakos E; Roussou Z; Clouva P; Maguina N; Kanellakopoulou K; Armaganidis A; Giamarellou H
    J Infect; 2009 Apr; 58(4):273-84. PubMed ID: 19344841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Results of tigecycline trials announced.
    McConnell J
    Lancet Infect Dis; 2004 Dec; 4(12):717. PubMed ID: 15593443
    [No Abstract]   [Full Text] [Related]  

  • 48. [Epidemiology and risk factors of patients with intra-abdominal postsurgical infection treated with tigecycline: a cohort study].
    Torres G; Paredes M; Hernández A; García C; Sánchez Bueno F; Canteras M; Parrilla P; Gómez J
    Rev Esp Quimioter; 2017 Feb; 30(1):28-33. PubMed ID: 28010058
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective.
    Teras J; Gardovskis J; Vaasna T; Kupcs U; Pupelis G; Dukart G; Dartois N; Jouve S; Cooper A;
    J Chemother; 2008 Oct; 20 Suppl 1():20-7. PubMed ID: 19036671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
    Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.
    Falagas ME; Vardakas KZ; Tsiveriotis KP; Triarides NA; Tansarli GS
    Int J Antimicrob Agents; 2014 Jul; 44(1):1-7. PubMed ID: 24602499
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Retrospective analysis of tigecycline shows that it may be an option for children with severe infections.
    Zhu ZY; Yang JF; Ni YH; Ye WF; Wang J; Wu ML
    Acta Paediatr; 2016 Oct; 105(10):e480-4. PubMed ID: 27381360
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tigecycline: an update.
    Stein GE; Babinchak T
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tigecycline for the treatment of severe Clostridium difficile infection.
    Larson KC; Belliveau PP; Spooner LM
    Ann Pharmacother; 2011 Jul; 45(7-8):1005-10. PubMed ID: 21730279
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome.
    Kim NH; Hwang JH; Song KH; Choe PG; Kim ES; Park SW; Kim HB; Kim NJ; Park WB; Oh MD
    Scand J Infect Dis; 2013 Apr; 45(4):315-9. PubMed ID: 23113680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monomicrobial bone and joint infection due to Corynebacterium striatum: literature review and amoxicillin-rifampin combination as treatment perspective.
    Noussair L; Salomon E; El Sayed F; Duran C; Bouchand F; Roux AL; Gaillard JL; Bauer T; Rottman M; Dinh A
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1269-1278. PubMed ID: 30903537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections.
    Bartoletti M; Tedeschi S; Pascale R; Raumer L; Maraolo AE; Palmiero G; Tumietto F; Cristini F; Ambretti S; Giannella M; Lewis RE; Viale P
    Int J Antimicrob Agents; 2018 Mar; 51(3):516-521. PubMed ID: 29410250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pediatric acute pancreatitis related to tigecycline.
    Prot-Labarthe S; Youdaren R; Benkerrou M; Basmaci R; Lorrot M
    Pediatr Infect Dis J; 2010 Sep; 29(9):890-1. PubMed ID: 20720475
    [No Abstract]   [Full Text] [Related]  

  • 59. Daptomycin > 6 mg/kg/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center.
    Roux S; Valour F; Karsenty J; Gagnieu MC; Perpoint T; Lustig S; Ader F; Martha B; Laurent F; Chidiac C; Ferry T;
    BMC Infect Dis; 2016 Feb; 16():83. PubMed ID: 26888539
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.
    Ellis-Grosse EJ; Babinchak T; Dartois N; Rose G; Loh E; ;
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S341-53. PubMed ID: 16080072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.